The call presented a largely positive operational and financial performance for 2025: strong cash generation, improved profitability, high net revenue retention (116%), productivity gains, meaningful DAAP momentum and a $10M share repurchase authorization. However, management flagged near-term top-line risks driven by a market shift away from managed services, conservative client behavior tied to MFN negotiations, shorter contract durations, and a Q4 gross margin mix that is unlikely to repeat. Guidance for 2026 is conservative on revenue (flat to modestly higher) while maintaining healthy adjusted EBITDA expectations, reflecting a focus on profitability and cash usage for debt reduction and opportunistic buybacks. Overall, the positives around profitability, cash flow, recurring-revenue progress and customer traction outweigh the near-term revenue headwinds.

Company Guidance

Management updated 2026 guidance to revenue of $109–$114 million and adjusted EBITDA of $21–$25 million, taking a more conservative top‑line view despite fiscal 2025 strength (FY2025 revenue $109.4M, adjusted EBITDA $24.3M; Q4 revenue $32.2M, Q4 adjusted EBITDA $12M), having achieved Rule of 40 and adjusted EBITDA margins above 20%, generated nearly $19M free cash flow (operating cash flow $18.7M), ended the year with $23.4M in cash and short‑term investments against $26.3M of debt, saw Q4 gross margin of 74.8% but expects mid‑60% gross margin in 2026, noted managed‑services drove roughly $9M of 1H25 revenue and will be minimal in 2026, contracted revenue is running ~15–20% below prior year ex‑managed services, net revenue retention is 116%, average revenue per top‑20 pharma $2.8M (down from $3.0M), revenue per FTE $839K (up from $701K), and the Board authorized a $10M share repurchase program while prioritizing debt paydown and profitable growth.

Quarterly and Full-Year Revenue & Profitability

Q4 revenue of $32.2M and full-year 2025 revenue of $109.4M. Q4 adjusted EBITDA of $12.0M and full-year adjusted EBITDA of $24.3M, delivering adjusted EBITDA margins above 20% for the year and achieving Rule of 40 performance.

Strong Cash Generation and Balance Sheet Improvement

Operating cash flow for 2025 was $18.7M versus $4.9M in 2024 (+~281.6%), and free cash flow nearly $19M for the year. Cash and short-term investments rose to $23.4M from $13.4M at year-end 2024 (+~74.6%). Company paid down $8M in principal during 2025 (including $6M early).

Profitability and Earnings Upside

Q4 non-GAAP net income was $9.9M ($0.51/sh) vs $5.5M ($0.30/sh) year-ago (+80%). GAAP Q4 net income was $5.0M ($0.26) vs a net loss of $0.1M in Q4 2024. Adjusted EBITDA in Q4 increased to $12.0M from $8.8M (+36.4%). Management states adjusted EBITDA and free cash flow more than doubled year-over-year.

Gross Margin Expansion (Quarterly)

Q4 gross margin expanded to 74.8% from 68.1% in the year-ago quarter (+6.7 percentage points), driven by a favorable solution and channel partner mix and higher-margin specialty messaging.

High Net Revenue Retention and Productivity Gains

Net revenue retention remained strong at 116%. Revenue per FTE improved to $839,000 from $701,000 in the prior year (+~19.7%), indicating improved productivity.

Commercial Momentum and DAAP Adoption

Expanded multi-brand enterprise engagements (notably in oncology and med tech) with pilot-to-scale DAAP adoption. Exit-2025 run-rate for DAAP-to-subscription conversion approached ~10%, up from a 5%-10% full-year 2025 range, showing progress toward recurring revenue.

Capital Allocation & Shareholder Return

Board authorized a $10M share repurchase program to be funded from available cash. Management plans to opportunistically balance debt paydown and buybacks, with priority on accelerating debt reduction.

OptimizeRx (OPRX) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

OPRX Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Apr 30, 2026	2026 (Q1)	<0.01 / -	0.08	―	―	―
Mar 05, 2026	2025 (Q4)	0.22 / 0.51	0.3	70.00% (+0.21)	―
Nov 06, 2025	2025 (Q3)	0.04 / 0.20	0.12	66.67% (+0.08)	―
Aug 07, 2025	2025 (Q2)	0.02 / 0.24	0.02	1100.00% (+0.22)	―
May 12, 2025	2025 (Q1)	-0.12 / 0.08	-0.11	172.73% (+0.19)	―
Mar 12, 2025	2024 (Q4)	0.27 / 0.30	0.26	15.38% (+0.04)	―
Nov 13, 2024	2024 (Q3)	0.06 / 0.12	0.09	33.33% (+0.03)	―
Aug 08, 2024	2024 (Q2)	-0.06 / 0.02	-0.01	300.00% (+0.03)	―
May 14, 2024	2024 (Q1)	- / -	-0.09	―	―
Apr 16, 2024	2023 (Q4)	-0.13 / -0.11	-0.09	-22.22% (-0.02)	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

OPRX Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Mar 05, 2026	$7.53	$6.74	-10.49%
Nov 06, 2025	$18.94	$15.65	-17.37%
Aug 07, 2025	$12.84	$17.30	+34.74%
May 12, 2025	$9.20	$11.01	+19.67%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does OptimizeRx Corporation (OPRX) report earnings?

OptimizeRx Corporation (OPRX) is schdueled to report earning on Apr 30, 2026, TBA (Confirmed).

What is OptimizeRx Corporation (OPRX) earnings time?

OptimizeRx Corporation (OPRX) earnings time is at Apr 30, 2026, TBA (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is OPRX EPS forecast?

OPRX EPS forecast for the fiscal quarter 2026 (Q1) is <0.01.